RBC cuts target for Intuitive Surgical stock to USD 550.00

Published on 10/26/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value stood at USD 159.1 billion on October 26, 2026. Intuitive Surgical stock costs EUR 403.23 on October 26, 2026.

Analyst target and market position

Royal Bank of Canada cut its Intuitive Surgical target from USD 575.00 to USD 550.00 on October 21, 2026.
Intuitive Surgical carried a USD 159.1 billion market capitalization on October 26, 2026.
Intuitive Surgical stock cost EUR 403.23 at Lang & Schwarz on October 26, 2026 at 5:31 p.m. CEST.
The stock traded at a 54.19 trailing price-to-earnings ratio on October 26, 2026.

Intuitive Surgical, US46120E6023, Illustration mit AI erstellt.

Royal Bank of Canada cut its Intuitive Surgical price target from USD 575.00 to USD 550.00 in a research note dated October 21, 2026, while maintaining an outperform rating, according to MarketBeat. The new target is 22.09 percent above the USD 450.50 Nasdaq price at 12:33 p.m. EDT on October 26, 2026. Intuitive Surgical was trading at EUR 403.23 at Lang & Schwarz on October 26, 2026 at 5:31 p.m. CEST.

The target remains above the market

The target reduction still leaves a USD 99.50 gap to the latest Nasdaq price. Royal Bank of Canada retained its outperform view, placing the target 22.09 percent above that USD 450.50 market price.

Price position after October 20

Intuitive Surgical's Nasdaq price stood at USD 450.50 on October 26, 2026 at 12:33 p.m. EDT, down USD 1.79 on the session. Its 52-week range was USD 328.57 to USD 603.88, while market capitalization stood at USD 159.1 billion on the same date.

The company traded at a trailing price-to-earnings ratio of 54.19. That valuation measure places the stock above Medtronic's 23.26 ratio, while Abbott Laboratories traded at 38.72 on October 26, 2026.

What do the quarterly figures mean?

Intuitive Surgical reported USD 3.05 billion in third-quarter 2026 revenue on October 20, 2026, up 22.00 percent from USD 2.51 billion in the third quarter of 2025, according to Intuitive Surgical. GAAP net income was USD 522.8 million, or USD 1.49 diluted earnings per share, compared with USD 704.4 million, or USD 1.95, in the third quarter of 2025. A litigation charge reduced the reported result, while adjusted earnings per share reached USD 3.00 against a FactSet estimate of USD 2.65, Morningstar reported.

Comparison with peers

Intuitive Surgical: down 0.40 percent on Nasdaq, price-to-earnings ratio 54.19, market capitalization USD 159.1 billion.

Abbott Laboratories (NYSE, USD): up 0.82 percent, price-to-earnings ratio 38.72, market capitalization USD 180.9 billion.

Medtronic (NYSE, USD): down 1.05 percent, price-to-earnings ratio 23.26, market capitalization USD 120.8 billion.

Valuation and reporting date

The latest reported quarter ended September 30, 2026, and the earnings announcement was dated October 20, 2026. The reported revenue growth and the analyst target revision now provide two distinct reference points for assessing the stock's valuation.

The valuation gap is measurable

At USD 450.50 on Nasdaq and EUR 403.23 at Lang & Schwarz, Intuitive Surgical combines strong third-quarter revenue growth with a high trailing valuation and a reduced, but still higher, analyst target. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.